Episode 1, Series 1. How I treat ER/PR+, Her-2 negative early breast cancer

Dr Abi Jenner explains how she treats ER/PR positive, HER-2 negative early breast cancer. She discusses staging, the role of chemotherapy, in part directed by oncotype analysis, hormonal therapy, and the role of exercise in patients with breast cancer.

The Bristol Oncology Podcasts's podcast

The Bristol Oncology Podcasts


Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano, M.D., Robert J. Gray, Ph.D., Della F. Makower, M.D., Kathleen I. Pritchard, M.D., Kathy S. Albain, M.D., Daniel F. Hayes, M.D., Charles E. Geyer, Jr., M.D., Elizabeth C. Dees, M.D., Matthew P. Goetz, M.D., John A. Olson, Jr., M.D., Ph.D., Tracy Lively, Ph.D., Sunil S. Badve, M.B., B.S., M.D., et al.
NEJM 2018: 379; 111-121

The TailorX study. This trial shows the non-inferiority of de-escalating therapy for patients with intermediate oncotype risk score, treating with hormonal therapy, rather than chemotherapy and hormonal therapy

View Online
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
P.A. Francis, O. Pagani, G.F. Fleming, B.A. Walley, M. Colleoni, I. Láng, H.L. Gómez, C. Tondini, E. Ciruelos, H.J. Burstein, H.R. Bonnefoi, M. Bellet, S. Martino, C.E. Geyer, Jr., M.P. Goetz, V. Stearns, G. Pinotti, F. Puglisi, S. Spazzapan, M.A. Climent, L. Pavesi, T. Ruhstaller, N.E. Davidson, R. Coleman, M. Debled, S. Buchholz, J.N. Ingle, E.P. Winer, R. Maibach, M. Rabaglio‐Poretti, B. Ruepp, A. Di Leo, A.S. Coates, R.D. Gelber, A. Goldhirsch, and M.M. Regan, for the SOFT and TEXT Investigators and the International Breast Cancer Study Group
NEJM 2018: 379; 122-37

The SOFT and TEXT trials of adjuvant hormonal therapy

View Online